Exosome Diagnostics, a Bio-Techne brand

Exosome Diagnostics, Inc., founded in 2008 and headquartered in the United States, is making significant strides in the biotechnology and healthcare industries. The company's slogan, "ExoDx Prostate is the only exosome-based, non-DRE, simple urine test to assess risk for HGPCa and guide biopsy decision," encapsulates its pioneering approach. Exosome Diagnostics is focused on commercializing minimally invasive molecular diagnostics in blood and urine, offering a breakthrough in guiding physicians to select optimal therapies for cancer and other diseases. The company's innovation lies in its utilization of exosomes, which are lipid bilayer-covered microvesicles shed by solid tumors into body fluids. These exosomes contain nucleic acid profiles of cancers and other diseases, serving as valuable indicators for diagnosis and treatment selection. Notably, Exosome Diagnostics has achieved compelling results in extracting exosomes from patients' blood and urine, detecting key genes and gene mutations associated with various cancers with high sensitivity and specificity. In their last funding round in July 2017, Exosome Diagnostics secured a substantial $30.00M Series C investment. This capital injection was provided by a distinguished group of investors including Forbion, Arcus Ventures, NGN Capital, Tiger Infrastructure Partners, b2venture (formerly btov Partners), CD-Venture, and Blue Ridge Capital. This financial backing is a testament to the confidence placed in Exosome Diagnostics' groundbreaking approach and its potential to revolutionize diagnostics and treatment selection in the healthcare industry.